News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Pharma: Strengthening And Extension Of The Industrial Protection Of Livatag® Until 2031


2/18/2014 10:11:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products, announced today a major strengthening of the patent protection for its product Livatag® (doxorubicine Trandrug™), currently in phase III clinical trial in primary liver cancer (ReLive trial).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES